The startup develops therapeutic antibodies that target specific antigens on solid and hematological tumors, enhancing the immune response against cancer cells. By focusing on novel targets in immuno-oncology, the company aims to improve treatment efficacy for patients with various tumor types.
Funding
$440K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Apoptotic cell death, mediated by the interaction of FasL with its receptor Fas, contributes to the pathology of various diseases, including cancer, retinal diseases, and viral infections. In cancer, FasL-mediated T-cell depletion hinders effective immune responses against tumors. In retinal diseases, FasL contributes to the death of retinal ganglion cells and retinal pigmented epithelial cells, leading to vision loss.
Solution
FasT Biopharma develops therapeutic antibodies that block the FasL pathway to prevent unwanted cell death in various disease settings. Their lead candidates, FBP001 and FBP002, are designed to neutralize FasL, thereby preventing its interaction with the Fas receptor and subsequent apoptosis. FBP001 is specifically designed for intravitreal delivery to treat retinal diseases like glaucoma and dry age-related macular degeneration by inhibiting the death of retinal cells. FBP002, a humanized monoclonal antibody, is designed for intravenous administration to treat cancers, particularly metastatic colorectal cancer, by preventing T-cell depletion and enhancing anti-tumor immunity.
Target Audience
The primary target audience includes patients suffering from retinal diseases such as glaucoma and dry age-related macular degeneration, as well as patients with metastatic colorectal cancer.
Features
- FBP001: A therapeutic antibody designed for intravitreal delivery to treat retinal diseases by blocking FasL-mediated cell death in the eye.
- FBP002: A humanized monoclonal antibody engineered for intravenous administration to treat cancers by preventing FasL-mediated T-cell depletion.
- Designed to provide extended duration of action.
- Targets FasL to prevent apoptotic cell death in diseases where this pathway is dysregulated.